Thursday 7 May, 2026
INTRODUCTION: In biochemistry and its applied sciences such as pharmacology, first-order rate constants (FORCs) are used in kinetic models to…
Read moreAbstracts
QUANTIFYING THE IMPACT OF LLOQ AND ULOQ CENSORING ON M3 ESTIMATION PERFORMANCE IN NONMEM
Thursday 7 May, 2026
Introduction/objectives : The analysis of pharmacokinetic (PK) clinical data is frequently complicated by censored observations, which may affect data representativeness…
Read moreNew benchmarks for FOCE
Thursday 7 May, 2026
Introduction: The First-Order Conditional Estimation (FOCE) method remains central to the application of non-linear mixed-effects models in pharmacometrics. Datasets of…
Read moreTranslational prediction of pharmacologically active metabolite contribution to the relative efficacy of TBAJ-587 for early clinical development
Thursday 7 May, 2026
Introduction: Active metabolites of drugs under clinical development require evaluation of their quantitative and qualitative contributions to the overall pharmacological…
Read moreDISEASE-INFORMED PBPK MODELLING OF RIFAMPICIN: MECHANISTIC INTEGRATION OF BILE SALT–MEDIATED DISSOLUTION TO PREDICT PHARMACOKINETIC VARIABILITY IN HEPATOBILIARY CONDITIONS
Thursday 7 May, 2026
Objectives Rifampicin is a BCS Class II antibiotic whose absorption is governed by solubility-limited dissolution regulated by bile salt–associated micellar…
Read morePopulation pharmacokinetics of [177Lu]Lu-PSMA-617 combined with EBRT and ADT in treatment naïve patients: differences in tumor uptake and cycle-dependent-effects
Thursday 7 May, 2026
Objectives: [¹⁷⁷Lu]Lu-PSMA-617 is an approved radioligand therapy that prolongs survival in metastatic castration-resistant prostate cancer (PCa). The PROQURE‑I trial investigated…
Read moreIntegration of mechanistic pharmacokinetic models with gene regulatory networks for early detection of resistance in Chronic Lymphocytic Leukaemia
Thursday 7 May, 2026
Background: Chronic Lymphocytic Leukaemia (CLL) exhibits heterogeneous therapeutic responses, with a substantial subset of patients developing resistance to standard treatments….
Read moreImpact of the use of different PK/PD indexes on amikacin dosing requirements in severely ill children: a population PK approach
Thursday 7 May, 2026
Introduction: Amikacin is a critical antibiotic for treating severe infections in immunocompromised children. Pediatric patients are particularly vulnerable due to…
Read moreAccounting for Cell Settling Is Critical for Accurate In Vitro Trimer Formation Modeling of T Cell Engagers
Thursday 7 May, 2026
Introduction: In vitro trimer formation modeling is commonly used to predict the dose at which pharmacological activity is observed for…
Read moreTOWARD A QUANTITATIVE SYSTEMS PHARMACOLOGY FRAMEWORK OF CELL-LEVEL ALPHA-SYNUCLEIN DYNAMICS
Thursday 7 May, 2026
Objectives: Parkinson’s disease (PD) – the second most prevalent neurodegenerative disorder worldwide [1] – is characterized by the progressive accumulation…
Read more